Multiple Sclerosis Journal

Background and Objectives: Cognitive impairment is common in multiple sclerosis (MS), but whether brain age gap (BAG) has greater cognitive relevance in MS than in people without brain disease is not known. We tested whether BAG was more strongly associated with cognitive processing speed (CPS) in MS. Methods: We performed a cross-sectional analysis of MRI-derived BAG and CPS from a UK Biobank study consisting of 21,117 normative reference subjects with no recorded brain disease and 97 subjects with MS. BAG and CPS were standardized to the normative reference distribution, and an age- and sex-adjusted interaction tested whether the association differed between groups. Separately, a meta-analysis of the relationship of BAG and CPS was performed using published data from five independent MS cohorts (n=1,250 subjects in total). Correlation statistics were pooled to establish the effect size, 95% confidence intervals and p-values. Results: In UK Biobank, there was a moderate negative association between BAG and CPS in MS (r=-0.35, 95% CI -0.52 to -0.17; P<.001), whereas the association in the normative reference group was negligible (r=-0.05, 95% CI -0.07 to -0.04; P<.001). There was a BAG-by-MS interaction indicating an MS-specific correlation (beta =-0.19, 95% CI -0.29 to -0.09; P<.001). Across five independent clinical MS cohorts, the pooled BAG-CPS correlation was r=-0.25 (95% CI -0.33 to -0.18; P<.001). Overall, the magnitude of the association between BAG and CPS was at least five-fold greater in MS than in the normative population. Conclusion: BAG was substantially more strongly associated with CPS in MS than in the normative population. These cross-sectional findings support further evaluation of BAG as an adjunctive MRI marker. Further studies are required to establish mechanism, prognosis, or clinical decision utility.

Background: Pregnancy is a distinct neuroendocrine and immunological state in women with multiple sclerosis (MS). Relapse activity typically decreases during gestation and increases after delivery, but the relationship between peri-pregnancy brain volumetric measures and disability remains unclear. Methods: This retrospective longitudinal pilot study included 14 women with relapsing-remitting MS who underwent MRI examinations before pregnancy and after delivery. Thirty-eight MRI scans were analyzed, with a mean of 2.71 timepoints per patient (SD 0.99). Global and regional brain volumes were measured using the longitudinal FreeSurfer pipeline. Choroid plexus (CP) volume was evaluated as an exploratory neuroimmune imaging marker. Associations between volumetric measures and Expanded Disability Status Scale (EDSS) scores were assessed using linear mixed-effects modeling with forward stepwise selection. Results: The final EDSS model retained bilateral ventral diencephalon (ventral DC) volumes, left amygdala volume, right pallidum volume, left nucleus accumbens volume, and cerebral cortex volume. The most prominent association involved the left ventral DC, where lower volume was associated with higher EDSS scores (p = 0.0008). CP volume showed no significant longitudinal change across peri-pregnancy MRI timepoints (p = 0.21) and was not retained in the final EDSS model. Conclusion: Regional brain volumetric measures, particularly ventral DC volumes, were associated with disability across the peri-pregnancy period despite low EDSS levels. To our knowledge, this is the first longitudinal evaluation of CP volume across the peri-pregnancy period in women with MS; no significant change was observed over time. These exploratory findings require confirmation in larger prospective studies using standardized serial MRI protocols.

Background: Brain age is a biomarker of brain tissue integrity associated with disability in multiple sclerosis. While new lesion formation is central to MS diagnosis and treatment monitoring, its direct relationship to brain aging has not been established. Methods: We analyzed 163 people with MS with clinical and MRI assessments at baseline and years 3, 6, and 8. Brain age was estimated using BrainAgeNeXt. Annualized brain age acceleration was modeled as a function of radiological activity using generalized estimating equations, adjusting for age, sex, disease duration, baseline T2 lesion volume, normalized brain volume (NBV), brain age difference (BAD), and disease-modifying therapy. Secondary analyses examined dose-response effects, post-activity recovery, paramagnetic rim lesion (PRL) associations, and disability associations. Results: 105 participants had at least one new T2 lesion over 8 years. Radiologically active intervals (138 of 333) were associated with +0.19 yr/yr greater brain age acceleration than stable intervals (95% CI: 0.03-0.37; p=0.022), scaling with lesion count (beta=+0.18; p=0.001) and volume. Older age, greater baseline BAD, and NBV were independently associated with reduced brain age acceleration. Brain age acceleration in individuals with new lesions normalized during subsequent stable intervals (0.41 vs -0.06 yr/yr; p=0.001). Both PRLs and non-PRL lesions were associated with greater brain age acceleration than stable intervals. Baseline BAD, but not annualized acceleration, predicted Expanded Disability Status Scale (EDSS) and Nine-Hole Peg Test (9HPT) worsening. Conclusions: New focal lesion formation is associated with a quantifiable, dose-response acceleration of brain aging in MS that normalizes once lesion activity is suppressed.

OBJECTIVE: To prioritize novel measures of disease progression, we examined whether actigraphy-derived rest-activity rhythm (RAR) parameters relate to cognitive performance as well as disability in a multiple sclerosis (MS) cohort enrolled in a prospective brain donation program. METHODS: RAR parameters were assessed using a wrist actigraphy device (AX3 Axivity Actiwatch, Axivity Ltd.) over two weeks. The primary outcome measure was the Symbol Digit Modalities Test (SDMT, N=222). Secondary outcomes included Brixton Spatial Anticipation Test and self-reported disability. In 76 participants, volumetric measures were derived from repurposed clinical magnetic resonance imaging (MRI) data. We applied linear and logistic regression models, adjusting for age, sex, education, time since MS diagnosis, and body mass index. RESULTS: After correction for multiple comparisons, higher intradaily variability (IV) of RAR and lower relative amplitude were associated with worse SDMT performance; higher IV was also associated with greater odds of disability. A broader set of RAR parameters was associated with disability measure. No MRI parameters were related to RAR in the subset of individuals with available MRI data, although we note suggestive associations with hippocampal and choroid plexus volumes warranting further investigation. INTERPRETATION: More robust circadian rhythms were related to better cognition. These results highlight the utility of actigraphy and its more nuanced measures beyond the simple summaries of activity levels that quantitate the extent of motor disability. Selected RAR features may be an effective non-invasive approach to capture clinically relevant quantitative measures of brain function for persons with MS.

Background: Secondary progressive multiple sclerosis (SPMS) is traditionally viewed as predominantly neurodegenerative, with limited inflammatory activity. However, chronic active lesions characterised by persistent rim inflammation and gradual expansion may continue to contribute to tissue injury. Objectives: To characterise chronic lesion dynamics in SPMS and determine whether chronic lesion expansion contributes to tissue damage and neurodegeneration. Thirty-one patients with SPMS underwent longitudinal MRI including T1-weighted, FLAIR and diffusion imaging. White matter lesions were manually segmented and chronic lesion tissue expansion (CLTE) was quantified as annualised percentage change. Associations between lesion expansion, mean diffusivity (MD) changes and brain atrophy were assessed using correlation, regression and mixed-effects modelling. Results: CLTE remained prominent, with a mean annual expansion rate of 7.1 +- 4.1%. Expansion substantially exceeded the contribution of newly formed lesions and occurred at rates comparable to relapsing multiple sclerosis. CLTE demonstrated moderate intra-patient clustering (ICC = 0.23). MD increased significantly within lesions during follow-up and was associated with lesion expansion. Chronic lesion expansion was also strongly associated with ventricular enlargement (partial r = 0.72, p < 0.001). Conclusions: Chronic lesion expansion persists in SPMS and represents a major source of tissue injury associated with microstructural degeneration and brain atrophy.

Background: Optic nerve involvement is common in multiple sclerosis (MS) and is now recognized as a key site for dissemination in space under the most recent revision of McDonald's criteria. Reliable detection of optic nerve lesions is essential for diagnosis and monitoring, yet the optimal MRI sequence remains uncertain. Objective: To compare the diagnostic performance of three MRI sequences - short tau inversion recovery (STIR), fat-suppressed FLAIR (fs-FLAIR), and double inversion recovery (DIR)- in detecting optic nerve lesions in MS patients. Methods: Fifty-nine MS patients underwent MRI with STIR, fs-FLAIR, and DIR sequences and visual evoked potential (VEP) testing. Lesion detection was assessed independently for each sequence, and results were compared to structural and functional standards. Results: No significant differences were found in lesion detection across the three sequences. All sequences showed similar sensitivity to structural and functional changes. The incremental benefit of adding orbita specific sequence to a whole-brain sequence was limited in the follow-up of MS. Conclusion: In patients with established MS, whole-brain sequences (fs-FLAIR, DIR) perform comparably to dedicated orbital sequences (STIR) in detecting optic nerve lesions. This supports the feasibility of MRI protocols by omitting additional orbital sequences in routine follow-up, thereby reducing scan time and patient burden without compromising diagnostic sensitivity.

Word-finding difficulty (tip-of-the-tongue phenomenon) is among the most prevalent changes reported by persons with multiple sclerosis (MS), but we lack validated performance metrics to assess this common symptom. Antonyms is a novel task evaluating retrieval of target phonological codes via a brief, clinically-feasible paradigm that controls for other cognitive processes. Test-retest reliability was good (0.85). Among 660 patients, Antonyms demonstrated better criterion validity than traditional language tasks (e.g., animal generation, Boston Naming Test). Demonstrating discriminate validity, Antonyms was specifically related to patient-reported difficulties with expressive language rather than working memory, executive/speed, or episodic memory. The Antonyms task is provided herein.

Background: Real-world evidence evaluating the long-term effectiveness and safety of dimethyl fumarate (DMF) in relapsing-remitting multiple sclerosis (RRMS) remains limited, particularly in Middle Eastern populations. Furthermore, whether previous exposure to disease-modifying therapies influences longitudinal treatment response has not been adequately characterized. We evaluated the real-world effectiveness, safety, and temporal treatment dynamics of DMF in RRMS and compared outcomes between treatment-naive and previously treated patients. Methods: This longitudinal observational cohort study enrolled 120 adults with RRMS initiating DMF (TECRA (R)) at two multiple sclerosis centers in Iran. Clinical outcomes, magnetic resonance imaging (MRI) activity, disability progression, and adverse events were assessed over 18 months at 6-month intervals. Repeated Expanded Disability Status Scale (EDSS) measurements were analyzed using linear mixed-effects models, while relapse counts and MRI lesion activity were evaluated using generalized estimating equations. Prespecified subgroup analyses examined differences according to prior treatment status. Results: Ninety-five patients completed the study. DMF produced a marked suppression of disease activity, reducing the annualized relapse rate by 95% (1.56 {+/-} 0.93 to 0.08 {+/-} 0.24; P < 0.001). EDSS improved during the first year and remained near baseline after 18 months despite a modest increase during the final follow-up interval. MRI inflammatory activity declined significantly throughout follow-up, although a mild increase in gadolinium-enhancing lesions after 12 months suggested possible attenuation of treatment effect over time. Overall, 88.4% of patients remained relapse-free, 70.5% demonstrated no MRI disease activity, and 64.2% achieved no evidence of disease activity (NEDA-3). While overall clinical outcomes were comparable between treatment-naive and previously treated patients, longitudinal analyses revealed distinct temporal patterns of MRI activity between groups. DMF was well tolerated, with predominantly mild cutaneous and gastrointestinal adverse events and infrequent treatment discontinuation. Conclusions: In conclusion, DMF was well tolerated and effective in reducing clinical and radiological disease activity. These findings support the long-term effectiveness of DMF in routine clinical practice while highlighting the importance of continued clinical and radiological monitoring to optimize individualized treatment strategies.

Background: Rituximab is used off-label for multiple sclerosis (MS), and biosimilar substitution raises a distinct extrapolation challenge, as MS is not an approved indication for the reference product. Real-world nonmedical switching data inform biosimilar appropriateness decisions by clinicians, societies, and payers. Objective: To report the effectiveness and tolerability of nonmedical switching from originator (MabThera) to biosimilar rituximab (Truxima) in people with MS (pwMS). Methods: A retrospective, single-center observational cohort study of 50 pwMS switched after at least two originator infusions, followed for two years. Results: Annualized relapse rate declined from 0.45 (95% CI 0.28 - 0.68) prerituximab to 0.02 (95% CI 0.00 - 0.13) on originator and 0.00 (95% CI 0.00 - 0.05) on biosimilar (p = 0.367 between products). In paired imaging analysis (n = 29), the proportion with active scans declined progressively (50.0%, 34.5%, 17.2%; Cochrans Q, p = 0.040), with no difference between the originator and biosimilar periods (McNemar, p = 0.227). B-cell depletion deepened progressively. All patients remained on biosimilar through the end of follow-up. Conclusion: Nonmedical switching from originator to biosimilar rituximab was associated with comparable clinical and radiological outcomes, supporting its use in pwMS without concern for inferior efficacy or diminished tolerability.

Objective To examine whether prospectively recorded maternal BMI in early pregnancy is associated with offspring multiple sclerosis (MS) risk, including childhood-onset and adult-onset MS. Design Nationwide population-based cohort study. Setting Swedish national health and demographic registers. Participants 1,524,863 singleton children born in Sweden from 1992 to 2007 and followed through 2025. Exposures Maternal BMI recorded at the first antenatal visit, categorised as underweight (<18.5), normal weight (18.5-24.9), overweight (25.0-29.9), and obesity ([&ge;]30.0), and also modelled continuously. Main outcome measures MS in offspring, identified as at least three ICD-10 G35 codes recorded on separate dates. Cox models estimated adjusted hazard ratios (HR) and 95% confidence intervals (CI) adjusting for confounders. Results During follow-up, 1539 offspring (0.1%) were diagnosed with MS at a median age of 24 years (interquartile range, 20-27 years). MS incidence rates by maternal BMI category were 0.37 per 10,000 person-years for both underweight, and normal weight, 0.42 for overweight, and 0.45 for obesity. Compared with normal weight women, maternal overweight and obesity were associated with higher hazards of offspring MS, with adjusted HRs of 1.20 (95% CI, 1.05 to 1.37) and 1.35 (95% CI, 1.11 to 1.64), respectively. Onset-specific analyses showed similar findings for adult-onset MS and less precise but directionally consistent estimates for paediatric-onset MS. Each 1-unit increase in maternal BMI was associated with a 3%, 4%, and 3% higher hazard of overall, paediatric-onset, and adult-onset offspring MS, respectively. Conclusions In this population-based cohort study, higher maternal BMI were associated with an increased rate of MS in offspring. The findings provide large-scale prospective evidence that maternal adiposity may be related to offspring MS risk and support further investigation of the prenatal metabolic environment in the early-life origins of MS.

Background: Relapsing-remitting multiple sclerosis (RRMS) often progresses to secondary-progressive MS (SPMS), but diagnosis is typically retrospective, delaying potential interventions. Existing rule-based and machine learning approaches often lack prospective validation and provide no uncertainty estimates, limiting clinical adoption. Objective: To prospectively evaluate a conformal prediction (CP)-enabled random forest model for reproducing clinician-recorded disease course labels in the Swedish Multiple Sclerosis Registry (SMSReg) and compare its classifications with the Lorscheider criteria. Methods: The CP model was trained and calibrated on SMSReg-2022 (10,787 individuals, 85,461 hospital visits) and then validated on SMSReg-2025 (15,719 individuals, 45,077 hospital visits; not included in the SMSReg-2022 training/calibration/testing datasets). Performance was assessed at the hospital visit and individual levels and compared with the Lorscheider criteria. Results: The model maintained good calibration on the prospective dataset. At the per-hospital visit-level, the model accuracies were 92% (RRMS) and 95% (SPMS). At the individual level, sensitivity was 98%, specificity 89%, and F1-score 0.75. With clinician-recorded labels as reference, the model showed higher sensitivity than the Lorscheider criteria (98% vs. 71%), more transition assignments (90% vs. 57%), and higher F1-score (0.76 vs. 0.69). Conclusion: The CP-enabled model prospectively reproduced clinician-recorded disease course labels with calibrated uncertainty, supporting harmonization and decision support.

Background: Quantitative susceptibility mapping (QSM) exhibits phase cancellation between paramagnetic (e.g. iron) and diamagnetic (e.g. myelin/protein) sources, obscuring microstructural lesion heterogeneity in multiple sclerosis (MS). We evaluated whether biophysical {chi}-separation identifies clinically meaningful lesion phenotypes and whether reduced echo sampling preserves microstructural sensitivity. Methods: In this cross-sectional study of 183 people with multiple sclerosis (PwMS), we analyzed 3327 quality-controlled white matter lesions using 3T MRI with a five-echo gradient-recalled echo sequence (GRE5) and a subsampled two-echo dataset (GRE2). A hybrid framework combining unsupervised clustering on whole-lesion paramagnetic ({chi}para) and diamagnetic ({chi}dia) features with rule-based compartmental edge-core gradient assignment resolved MS lesion phenotypes. Intralesional microstructural properties were evaluated using linear mixed-effects models. Multivariable linear regressions assessed associations with physical disability (Expanded Disability Status Scale, EDSS; n = 158), cognitive processing speed (Symbol Digit Modalities Test, SDMT; n = 79), and disease duration (DD; n = 161), with sensitivity models adjusting for total lesion volume, count, or DD. Results: The framework identified four reproducible lesion phenotypes (Adjusted Rand Index = 0.924): Type 1 (22.7%; preserved {chi}dia), Type 2 (32.9%; high {chi}para without positive edge-core gradient), Type 3 (35.8%; attenuated {chi}dia), and Type 4 (8.6%; high {chi}para with a positive edge-core paramagnetic gradient). Higher EDSS was selectively associated with more negative signed {chi}dia within Type 4 lesions (whole: {beta} = -0.37, q = 0.020; core: {beta} = -0.37, q = 0.006; edge: {beta} = -0.34, q = 0.030) and Type 2 edge ({beta} = -0.33, q = 0.044). Type 4 core associations remained robust across sensitivity models adjusting for total lesion volume ({beta} = -0.35, q = 0.004), total lesion count ({beta} = -0.37, q = 0.008), and DD ({beta} = -0.32, q = 0.033). Abbreviated GRE2 attenuated Type 4 compartmental associations to non-significance (all q greater than 0.05; core: {beta} = -0.20, q = 0.215). Conclusions: Quantitative {chi}-separation identified four internally stable susceptibility-defined MS lesion phenotypes, revealing disability-associated tissue heterogeneity beyond total lesion burden. Higher EDSS was associated with more negative diamagnetic measures within Type 4 cores after adjustment for lesion burden, pointing toward complex intralesional non-myelin tissue remodeling or reactive astrogliosis. Two-echo subsampling may influence compartment-specific clinical associations. By uncoupling susceptibility sources, {chi}-separation provides a quantitative framework for characterizing disability-associated lesion heterogeneity.

Background: Multiple sclerosis subpial cortical lesions are prevalent and associated with disability but difficult to detect on MRI. Inversion recovery susceptibility weighted imaging with enhanced T2 weighting (IR-SWIET) and T1/T2 ratio imaging have been proposed for cortical lesion detection on 3 tesla (T) MRI. Objectives: To assess cortical lesion detection using IR-SWIET and T1/T2 ratio imaging. Methods: Cortical lesions were identified in 20 persons with MS (pwMS) independently on six image sets: T1 weighted (w) magnetization prepared 2 rapid acquisition gradient echoes (MP2RAGE) + T2w fluid attenuated inversion recovery (FLAIR) alone or with T1/T2, IR-SWIET single acquisition (x1), average of two (x2) or median of four (x4) acquisitions, or denoised single acquisition (IR-SWIETx1DN). In 10 additional pwMS with 7T-based cortical lesion segmentations, lesions were identified on MP2RAGE + FLAIR + IR-SWIETx1DN. Results: Median subpial lesions identified on MP2RAGE + FLAIR was 0 (interquartile range (IQR) 2) vs 0 with T1/T2 (IQR 1, p=0.07), 1 with IR-SWIETx1 (IQR 6, p=0.42), 5 with IR-SWIETx2 (IQR 5, p=0.008), 4 with IR-SWIETx4 (IQR 6, p=0.008), and 4 with IR-SWIETx1DN (IQR 6, p=0.008). Versus 7T, IR-SWIETx1DN detected subpial lesions with similar sensitivity to IR-SWIETx2. Conclusions: IR-SWIET, but not T1/T2, improves subpial cortical lesion detection. Denoising may be an efficient and sensitive alternative to multi-acquisition averaging.

Paramagnetic rim lesions are a subset of focal white matter lesions specific to multiple sclerosis that are chronically inflamed and are associated with increased tissue injury, brain atrophy, and clinical disability. The molecular mechanisms linking paramagnetic rim lesions to these progressive biological outcomes remain unclear. Glutamatergic dysregulation has been hypothesized as a mechanism of multiple sclerosis progression potentially via excitotoxicity, but lesion-specific involvement is unknown. Here, 7T MRI was used to investigate glutamate-related metabolic alterations in paramagnetic rim lesions. Glutamate-weighted chemical exchange saturation transfer, together with T1 mapping and quantitative susceptibility mapping, was evaluated across paramagnetic rim lesions, non-paramagnetic rim lesions, and normal-appearing tissues in participants with multiple sclerosis (n=20) and healthy controls (n=11). Glutamate-weighted chemical exchange saturation transfer contrast was significantly higher in paramagnetic rim lesions compared to non- paramagnetic rim lesions (+10.7%) and normal-appearing white matter (+13%), while no differences were observed in normal-appearing tissue between multiple sclerosis and healthy controls. Additionally, reduced glutamate-weighted chemical exchange saturation transfer contrast in normal-appearing tissues was associated with worse motor and dexterity performance, linking observed metabolic abnormalities to clinical disability. These results identify a distinct metabolic phenotype of paramagnetic rim lesions marked by elevated glutamate-weighted signal consistent with localized excitotoxic stress. This work also implicates lesion-specific glutamatergic dysregulation in paramagnetic rim lesion-related neurodegeneration and demonstrates the potential of metabolic MRI to probe pathogenic mechanisms in multiple sclerosis.

Progressive multiple sclerosis (PMS) lacks blood-based biomarkers of the neurodegenerative processes driving disability. We measured synaptopodin, a postsynaptic protein, in neuronal-enriched extracellular vesicles (NEVs) across two independent cohorts: the SPRINT-MS trial (n=184) and a real-world validation cohort (n=268). A one SD increase in baseline synaptopodin was associated with ~32% lower risk of confirmed disability progression in PMS (p=0.011), with the strongest effect in secondary PMS (SPMS) (~57% lower odds, p=0.019). This SPMS association was replicated in the validation cohort (~60% lower odds, p=0.009). Higher baseline synaptopodin was associated with future slower whole-brain atrophy and preserved microstructural integrity across MRI metrics (p=0.007-0.013). Longitudinal changes in NEV synaptopodin were associated with disability worsening (p=0.007) and paralleled MRI microstructural changes. NEV synaptopodin, but not NfL, was associated with confirmed disability progression in PMS participants with both biomarkers measured (HR 0.71 vs 1.12, p=0.007 vs 0.22 for NEV synaptopodin and NfL, respectively) and SPMS (HR 0.58 vs 1.10, p=0.003 vs 0.50). Adding synaptopodin, but not NfL, to a base model improved discrimination for disability progression in SPMS in both cohorts (e.g. validation AUC 0.755 to 0.838, p=0.005). These findings identify NEV synaptopodin as a prognostic and longitudinal, blood biomarker of synaptic integrity in PMS, particularly SPMS, complementing NfL.

Treatment targeting progressive multiple sclerosis (MS) have limited efficacy, as central nervous system (CNS) resident B cells are resistant to peripheral B cell depletion by antiCD20 monoclonal antibodies. CD19 targeted chimeric antigen receptor (CAR)T cells offer the promise to deplete B cells more extensively in both the peripheral and CNS compartments. Two adult participants with treatment-refractory progressive MS were treated with 0.33e8 autologous anti CD19 CAR T cells (mivocabtagene autoleucel, miv-cel) intravenously after a preconditioning regimen. Participant 1 (50's year old female, EDSS 6) had no cytokine release syndrome (CRS) or immune effector cell-associated neurotoxicity syndrome (ICANS). Participant 2 (60's year old female, EDSS 4.5) had grade 1 CRS and no ICANS. Expansion of CAR T cells in the cerebrospinal fluid (CSF) at Day 14 was noted in both participants, remarkably with sustained disappearance of disease-associated oligoclonal band (OCB) or normalization of IgG index despite peripheral naive B cell reconstitution. MRI and clinical outcomes showed sustained stability at Week 48. Serologic studies showed a decline in anti-Epstein Barr Virus seropositivity. Single cell myeloid and proteomic signatures showed a decline in proinflammatory profiles. In the 2 subjects with progressive MS reported here, low dose anti CD19 CAR T cell therapy (miv-cel) was safe, penetrated the CSF effectively, reduced intrathecal humoral activity, modulated peripheral immune tone, and appeared to stabilize EDSS scores. Overall, these results support the continued investigation of CAR T cell therapy in MS.

Background: Detecting higher order relationships in datasets of complex traits, such as multiple sclerosis (MS), has been challenging. Conventional statistics largely rely on comparing averages across groups and thereby discard important information on the underlying distribution of datapoints. The Genomic Information Field Theory (GIFT) overcomes this limitation by ranking individuals based on linear measures, for example immunoglobulin titres. The exact role of humoral immune responses against several human herpes viruses in a sex-dependent manner in MS is currently unknown. Materials and methods: We compared the performance of GIFT with conventional statistical frameworks to detect differences in the humoral immune response against 4 highly prevalent herpes viruses linked to an individuals susceptibility to develop MS in 200 MS patients and 137 healthy controls. Results: GIFT validated the well-known association that the Epstein Barr Virus (EBV) protein EBNA1 is strongly linked to MS susceptibility in both sexes. In contrast to conventional statistics, GIFT also identified association between herpes simplex virus, varicella zoster virus and the EBV VCA protein and female susceptibility to develop MS, whereas male MS susceptibility was only linked to CMV immunoglobulin levels. None of these associations was observed using conventional statistical tools. Conclusion and discussion: We here show for the first time that GIFT is able to detect novel associations in human immunoglobulin data linked to MS susceptibility, which remained undetected by conventional statistical frameworks. This shows the power of GIFT to detect complex phenotype-trait associations and underlying subgroups within populations.

The glymphatic system is the waste clearance pathway in the central nervous system. Although its dysfunction has been associated with several neurological disorders, its role in multiple sclerosis (MS) remains poorly understood. This system is thought to be particularly active during sleep, yet the relationship between sleep metrics and MRI-derived markers of glymphatic activity has been scarcely explored. In this study, we aimed to perform a multimodal magnetic resonance imaging (MRI) assessment of glymphatic function in MS and investigate its association with sleep parameters, clinical disability, disease duration and MRI-derived structural markers. The study included 22 patients (34.3{+/-}10.1 years; 16 female) with relapsing-remitting MS and 26 healthy controls (32.2{+/-}5.7 years; 18 female), all of whom underwent 3.0 Tesla MRI. Glymphatic function was assessed using diffusion tensor image analysis along the perivascular space (DTI-ALPS) index and global blood-oxygen-level-dependent (BOLD) signal-cerebrospinal fluid (CSF) coupling. In addition, sleep micro- and macrostructural features, clinical disability, disease duration, along with mean diffusivity (MD), lateral ventricular, choroid plexus volumes and lesion load were evaluated. Patients showed reduced DTI-ALPS index, though this difference became only a trend after controlling for MD. No significant group differences were observed in global BOLD signal-CSF coupling. However, in patients, the weaker coupling was associated with longer total sleep time, lower arousal index, greater disability and lateral ventricle enlargement, whereas the DTI-ALPS index showed no significant correlations with any of the measures. Together, these findings challenge the assumption that DTI-ALPS can serve as a reliable marker of glymphatic function in demyelinating diseases such as MS, where disease-related alterations in white matter microstructure can confound diffusion-based measures. In contrast, gBOLD-CSF coupling showed associations with sleep, clinical disability and structural changes in patients, despite the absence of a significant group-level difference. This finding suggests that gBOLD-CSF coupling may capture individual variability in glymphatic-related dynamics relevant to sleep and the clinical expression of MS.

Background. CNM-Au8, a catalytic nanocrystalline gold suspension, is proposed to support neuronal bioenergetics, but its effect on chronic lesion evolution in multiple sclerosis (MS) has not been reported. Objectives. To evaluate the effect of CNM-Au8 on chronic lesion tissue expansion (CLTE). Results. In this exploratory post hoc analysis of the VISIONARY randomised placebo-controlled trial, CLTE was quantified from serial FLAIR MRI. Fifty-five participants were included (CNM-Au8, n=40; placebo, n=15). Compared with placebo, CNM-Au8 was associated with lower lesion expansion rate (p=0.001; Cliffs =-0.58) and volume (p<0.001; Cliffs =-0.65). Conclusions. CNM-Au8 treatment was associated with substantially reduced chronic lesion tissue expansion.

Introduction: Neuroinflammation is a known pathophysiologic mechanism in multiple sclerosis and a proposed mechanism in fibromyalgia and myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS). Positron Emission Tomography (PET) imaging of the translocator protein (TSPO) has been widely used to measure neuroinflammation, though second-generation ligands are highly sensitive to a single nucleotide polymorphism, rs6971, resulting in high, mixed, and low affinity binders. It is unknown whether this polymorphism is associated with neuroinflammatory disorders. Materials and Methods: Eighty-six total participant genotypes for TSPO binding affinity were identified through Sanger sequencing (30 fibromyalgia, 21 ME/CFS, 11 multiple sclerosis, and 24 healthy controls). Associations between patient group and genotype were assessed with Fishers Exact test. Associations between genotype and symptom severity from self-report questionnaires were assessed with Kruskal-Wallis tests. Results: In the present study individuals with fibromyalgia, (ME/CFS), or multiple sclerosis were more likely to have a mixed- or low-affinity genotypes compared to healthy controls. Presence of the low or mixed genotypes were also associated with greater self-reported fatigue severity and depressive symptoms. Discussion: These findings should be confirmed in larger samples but suggest functional consequences of rs6971 polymorphism that may be related to the pathophysiology of pain and fatigue illnesses.